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Proinﬂammatory(TNF-α,IL -1β,andNO) andantiinﬂammatory (IL-10,CO)levels were assayedin serum,liver,andsmallbowel in
ordertoverifyahypotheticinﬂammatoryetiopathogenyofportalhypertensionthatcouldbethecauseofitsevolutiveheterogeneity.
Male Wistar rats were divided into one control group (n = 11) and one group with a triple stenosing ligation of the portal vein
(n = 23) after 28 days of evolution. In one subgroup of portal hypertensive rats, portal pressure, collateral venous circulation,
mesenteric vasculopathy, and liver and spleen weights were determined. In the remaining rats with portal hypertension TNF-α,I L -
1β, and IL-10 were quantiﬁed in liver and ileum by enzyme-linked immunosorbent assay. NO synthase activity was studied in liver
and ileum. CO and NO were measured in portal and systemic blood by spectrophotometry and Griess reaction, respectively. Portal
hypertensive rats with mayor spleen weight show hepatomegaly and mayor development of collateral circulation. Ileum release of
IL-10 (0.30 ± 0.12 versus 0.14 ± 0.02pmol/mg protein; P<. 01) is associated with a liver production of both proinﬂammatory
mediators (TNF-α:2± 0.21 versus 1.32 ± 0.60pmol/mg protein; P<. 05, IL-1β:1 9 .17 ± 2.87 versus 5.96 ± 1.84pmol/mg protein;
P = .005, and NO: 132.10 ± 34.72 versus 61.05 ± 8.30nmol/mL; P = .005) and an antiinﬂammatory mediator (CO: 6.49 ± 2.99
versus 3.03 ± 1.59pmol/mL; P = .005). In short-term prehepatic portal hypertension a gut-liver inﬂammatory loop, which could
be fundamental in the regulation both of the portal pressure and of its complications, could be proposed.
INTRODUCTION
Portal hypertension (PHI) is a clinical syndrome
which is usually secondary to intrahepatic or extrahep-
atic obstruction of portal ﬂow. It is characterized by a
pathological increase in portal pressure, associated with
splenomegaly, and by the development of portosystemic
collateral circulation which diverts portal ﬂow to the sys-
temic circulation bypassing the liver [1, 2, 3]. Moreover,
PHT is the main complication of cirrhosis and is respon-
sibleformostofitscommoncomplications:varicealhem-
orrhage, ascites, and portosystemic encephalopathy [4].
Making aneﬀo rtt ocr eat enewP HTmod elso rt oimp r o v e
previously existing ones is justiﬁed by the need to study
the physiopathological mechanisms of this frequent and
severe clinical syndrome for which several diﬀerent types
of medical [5, 6] and surgical [7]t r e a t m e n t sh a v eb e e n
proposed.
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Partial portal vein ligation (PVL) in the rat is the most
frequently used experimental model to study in the short
term the pathophysiology of prehepatic PHT [8, 9]. Con-
striction of the portal vein (PV) is immediately followed
by increased portal resistance and portal pressure as well
as decreased portal venous inﬂow [10]. Partial develop-
ment of portosystemic collaterals is found after 4 days of
PVL and, after two weeks of evolution most (95%) of the
increased portal blood is diverted from the liver by an ex-
tensive portocollateral vascular bed [9, 10]. Then, portal
resistance decreases to control values and the splanchnic
bloodﬂow,secondarytoadecreaseinthesplanchnicarte-
riolar resistance, increases, all of which contributes to the
maintenance of increased portal pressure [10, 11].
Therefore, until now PHT in the rat has always been
considered to be a hemodynamic impairment with much
more homogeneous alterations than those described in
human PHT because of a narrow range of PHT, grade
of portosystemic shunts, and hepatic atrophy [12]. How-
ever, this evolutive uniformity could not be veriﬁed from
our previous studies using a modiﬁed technique of PV
calibrated stenosis in the rat since the degree of hepatic102 Maria Angeles Aller et al 2005:2 (2005)
atrophy, splenomegaly, and portosystemic collateral cir-
culation that developed were variable [13]. A possible in-
ﬂammatory etiopathogeny of PHT could be one cause of
this evolutive heterogeneity. Thus, an increased inﬁltra-
tion of the intestinal mucosa and submucosa by mast cells
has been described in PHT rats [14]. These inﬂammatory
cells could be considered to be primed to a noxious stim-
ulus and this mechanism could be responsible for the in-
creased susceptibility of the PHT mucosa. If so, the ana-
phylactic degranulation of the mast cells may cause in-
ﬂammatory episodes that vary in number and duration
in each individual. This diﬀerence could explain the great
variability observed in prehepatic PHT in the rat.
In order to verify a hypothetic inﬂammatory
etiopathogeny of PHT we have studied some mediators
involved in an inﬂammatory response. These included
tumor necrosis factor-α (TNF-α), Interleukin-1β (IL-1β),
interleukin-10 (IL-10), nitric oxide synthase (NOS)
isoforms in tissue (liver and/or intestine), and nitric oxide
(NO) and carbon monoxide (CO) in serum in rats with
short-term prehepatic PHT.
MATERIAL AND METHODS
Animals
MaleWistarratsfromtheComplutenseUniversityVi-
varium in Madrid with body weights from 230 to 250g
were used. The experimental procedures employed in this
study are in accordance with the Guidelines for the care
and use of Laboratory Animals (1986) published in Spain
(Royal Decree 223/1988).
Experimentaldesign
The animals were divided for their study into three
groups: one control group (I), in which the animals did
not undergo any intervention, and two-subgroups (IIa
and IIb), in which prehepatic PHT by triple stenosing lig-
ation of the portal vein (TSLP) was carried out. All the
animals were sacriﬁced by ether overdose after 28 days
of evolution. In Group IIa portal pressure, collateral ve-
nous circulation, mesenteric vasculopathy, and hepatic
and spleen weights were studied. In Group IIb TNF-α,
IL-1β, and IL-10 levels were assayed in ileum, endothelial
nitric oxide synthase (eNOS) and inducible nitric oxide
synthase (iNOS) activity were measured in liver and in
intestine (duodenum, jejunum, and ileum). Finally, NO
and CO concentrations were quantiﬁed in PV, suprahep-
aticinferiorvenacava(SH-IVC),andinfrahepaticinferior
vena cava (IH-IVC) blood.
Portalveinstenosistechnique
The surgical technique used to produce PHT by TSLP
has been described previously [15]. In brief, while rats
were under ketamine hydrochloride (80mg/kg) and Xy-
lacin (12mg/kg) im anesthesia, the PV was isolated and
three stenosing ligations were performed in its superior,
medial, and inferior portions. The stenoses were cali-
bratedbyasimultaneousligation(4-0silk)aroundthePV
and a 20-gauge blunt-tipped needle. The midline incision
was closed on two layers with catgut and 3-0 silk.
Portalveinpressuremeasurement
The portal pressure is measured by an indirect tech-
nique of intrasplenic punction [16], inserting a 20G nee-
dleinthesplenicparenchymawhichis,inturn,connected
to a PE-50 tube. After verifying that free back blood ﬂow
was obtained, the catheter was then connected to a pres-
sure recorder (PowerLab 200ML 201) and to a transducer
(Sensonor SN-844) with a Chart V 4.0 computer pro-
gram (ADI Instruments). The system is calibrated before
eachexperiment.Thezeroreferencepointwasestablished
at 1cm above the operating table. Previous studies have
demonstrated an excellent correlation between the indi-
rect measurement of the portal pressure by intrasplenic
punctionandthedirectmeasurementbycanulationofthe
superior mesenteric vein [17].
Portosystemiccollateralcirculationstudymethod
Portal hypertension was conﬁrmed by the presence
of splenomegaly and portosystemic collateral circulation.
First, a midline abdominal incision with a large bilateral
subcostal extension was made and then the areas in which
the collateral venous circulation was developed, that is,
the splenorenal (SR), gastroesophageal (paraesophageal
collaterals (PE)), colorectal (hemorrhoidal or pararectal
collateral (PR)) and hepatic hilum (portoportal (PP) and
accessory hepatic vein (AHV)) [4], were carefully stud-
ied for the presence of increased collateral veins. The lat-
ter (AHV) reached the hepatic hilum following a pathway
between the left lateral and caudate hepatic lobes [18].
Grosssuperiormesentericveinstudy
Existence of dilation and tortuosity of the superior
mesenteric vein branches has been named mesenteric ve-
nous vasculopathy (MVV). Three grade s of MMV were
considered: (i) Grade 0: normal appearance of the supe-
rior mesenteric vein branches; (ii) Grade I: dilation and
tortuosity of the mentioned branches secondary to the
Pringle maneuver, and (iii) Grade II in which the dilation
and tortuosity of the superior mesenteric vein branches
were spontaneous.
Bloodextractionmethod
Blood samples (1mL) were drawn by puncture of the
IH-IVC and SH-IVC. After 15 minutes of centrifugation
at 1500g they were separated and transferred to sterile
polypropylenetubes.Theserumwasthenfrozenat −80◦C
until NO and CO were assayed.
Preparationoforganhomogenates
Liver and intestine (duodenum, jejunum, ileum) were
quickly dissected and frozen in dry ice. Frozen organ
samples were weighed on a Mettler balance (model AE
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transferred to 50mL polypropylene tubes (Falcon; Becton
Dickinson, Lincoln Park, NJ) containing lysis buﬀer (4 ◦C)
at a ratio of 10mL buﬀer/1g of wet tissue. Lysis buﬀer
consisted of 1mM phenylmethylsulfonyl ﬂuoride (PMSF;
Sigma Chemical Company) and 1µg/mL pepstatin A
(Sigma Chemical Company), aprotinin (Sigma Chemi-
cal Company), antipain (Sigma Chemical Company), and
leupeptin (Sigma Chemical Company) in 1x phosphate-
buﬀered saline solution of pH 7.2 (Bioﬂuids, Rockville,
Md) containing 0.05% sodium azide (Sigma Chemical
Company). Samples were homogenized for 30 seconds
with an electrical homogenizer (Polytron; Brinkmann In-
struments, Westminster, NY) at maximum speed, and the
tubes were immediately frozen in liquid nitrogen. The
samples were homogenized three times for optimal pro-
cessing. The supernatants were frozen at −80 ◦Ct oa l l o w
the formation of macromolecular aggregates. After thaw-
ing at 4 ◦C, the aggregates were pelleted at 3000g (4 ◦C),
and the ﬁnal organ homogenate volume was measured
with a graduated pipette [19]. The homogenates were
storedat −80 ◦Cuntilassayedforthequantitativepresence
of rat TNF-α,I L - 1 β, and IL-10 with a rat enzyme-linked
immunosorbent assay (ELISA).
IlealandliverTNF-α,IL-1β,andIL-10ELISA
Cytokine levels were measured using commercially
available (ELISA) speciﬁc kits (BioNOVA Cientiﬁca Ltd,
Madrid, Spain). The minimum detectable level of TNF-α
was 0.5pg/mL (n = 10). The intraassay variation ranged
from 3.1% (lower part of standard curve) to 4.2% (up-
per) and the interassay variation oscillated between 5.2%
and 5.6%. The minimum detectable level of IL-1β was
1.5pg/mL (n = 10). The intraassay variation ranged
from 3.5% (lower part of standard curve) to 4.3% (up-
per) and the interassay variation osciled between 6.1%
and 7.4%. The minimum detectable level of IL-10 was
2.5pg/mL (n = 10). The intraassay variation ranged from
4.2% (lower part of standard curve) to 7.5% (upper)
and the interassay variation osciled between 5.8% and
9.3%.
NOSactivity
NOS activity was calculated as the rate of conver-
sionof 14C-arginineincitrulline.Tissuewashomogenized
in 1mL of a buﬀer containing 10−2 M HEPES, 0.32M
sucrose, 10−4 M EDTA, 10−3 M dithiothreitol, soybean
trypsin inhibitor, 10µg/mL leupeptin, 2µg/mL aprotinin,
and 1mg/mL phenylmethanesulfonylﬂuoride and cen-
trifuged for 20 minutes at 100000g at 4 ◦C. An aliquot of
the ﬁnal supernatant was mixed with PBB containing cal-
ciumchloride, 14C-arginine,valine(toinhibitarginaseac-
tivity)andNADPH,andincubatedfor30minutesat37 ◦C.
After puriﬁcation in a Dowex (50W) column, radioactiv-
ity wasmeasured.Constitutive NOSiscalciumdependent
while the inducible isoform is not. In contrast, the argi-
nine analog N-methyl-L-arginine predominantly inhibits
iNOS. To identify the activity of both NOS isoforms we
usedeitherthecalciumchelatorEGTA(1.4mM)toisolate
theactivityoftheiNOSorN-methyl-L-arginine(140µM)
to isolate the activity of the constitutive NOS [20].
SerumNOassay
The serum NO content was measured by the Griess
reaction as nitrite concentration after nitrate reduction to
nitrite [21]. Brieﬂy, the samples were deproteinized by the
addition of sulfosalicylic acid. They were then incubated
for 30 minutes at 4 ◦C and subsequently centrifuged for 20
minutes at 12000g. After incubation of the supernatants
with E colischerichial nitrate reductase (37 ◦C, 30 min-
utes), 1mL of Griess reagent (0.5% naphthylethylenedi-
amine dihydrochloride, 5% sulfonilamide, 25% phospho-
ricacid)(Merck,Darmstad,Germany)wasadded.There-
action was performed at 22 ◦C for 20 minutes and the ab-
sorbance was measured at 546nm, using sodium nitrite
solution as a standard. The minimum detectable level of
NO was 0.1nmol/mL (n = 10). The intraassay variation
was 1.6% and the interassay variation 2.7%.
SerumCOassay
ToquantifytheamountofCO,hemoglobinwasadded
to bind CO as carboxyhemoglobin and the proportion of
carboxyhemoglobin was estimated [22]. For this purpose,
hemoglobin(4µM)wasgentlymixedwiththesampleand
1 minute was allowed to ensure maximum CO binding.
Then,samplesweredilutedwithphosphatebuﬀer(0.01M
monobasicpotassiumphosphate/dibasicpotassiumphos-
phate, pH 6.85) containing sodium hydrosulﬁte, allowed
to stand at room temperature for 10 minutes, and ab-
sorbance was read at 420 and 432nm against a matched
cuvette only containing buﬀer. The minimum detectable
level of CO was 1pmol/mL (n = 10). The intraassay vari-
ation was 2.9% and the interassay variation 6.8%.
Statisticalanalysis
The results are expressed as the mean ± the standard
deviation.Analysisofvariance(ANOVA),theDuncantest
and Student t for unpaired data were used for the statis-
tical comparison of the quantitative variables between the
diﬀerent groups. Chi-square test was used for compari-
son of the qualitative variables. The linear correlation be-
tween two mutually dependent variables was determined
andexpressedasthecorrelationcoeﬃcient(r).Theresults
are considered as statistically signiﬁcant if P<. 05.
RESULTS
Splenomegaly is always present in portal hyperten-
sive rats. Since in rats with portacaval anastomosis (PCA)
spleen weights correlated with portal pressure and preser-
vation of portal pressure after PCA provides metabolic
and nutritional beneﬁts [23], two subgroups were deﬁned
within the TSLP group: one group in which spleen/body
weight ratio was less than 0.29 (IIa; n = 9) and one group
with a spleen/body weight ratio higher than or equal to104 Maria Angeles Aller et al 2005:2 (2005)
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Figure 1. Residual plot showing the distribution of spleen
weights in all control and TSLP rats. The solid lines represent
the mean values for the overall group. The broken lines repre-
sent the mean value for the TSLP rats with lower spleen weights
(IIa) and the TSLP rats with higher spleen weights (IIb).
0.30 (IIb; n = 14) (Figure 1). The spleen weight increase
is signiﬁcant (P<. 001) in all TSLP rats, and this increase
is greater (P<. 001) in Group IIb compared to Group IIa
(Table 1).
The body weight increase after 28 days of evolution
was lower (P<. 001) in all portal hypertensive rats (Table
1). The liver weight to body weight ratio does not change
when all the animals with PHT are considered (Group II),
but it is smaller in comparison to control animals in the
subgroup of lower spleen weight (IIa) and increases in the
subgroup with greater spleen weight (IIb) (Table 1). As
shown in Table 2, portal pressure increases (P<. 001) in
rats with PHT, although we did not ﬁnd diﬀerences be-
tween the two subgroups of animals with diﬀerent spleen
weights. Portal pressure correlates with body weight in-
crease (r = 0.71; P = .03) in Group IIa, with lower spleen
weight. In Group IIb, with higher spleen weight, portal
pressureiscorrelatedwithbodyweightincrease(r = 0.56;
P = .03) and there is an inverse correlation between
portal pressure and liver/body weight ratio (r =− 0.75;
P = .002) and between portal pressure and spleen/body
weight ratio (r =− 0.68; P = .008) (Table 3).
Mesenteric vasculopathy, of either Grade I or II, is ob-
served in all the animals with PV (Table 2). Portosystemic
collateral circulation of superior and inferior SR, PE, and
PR types is developed in rats with PHT. Two categories
were established: one consisting in the development of 1
to 3 types of collateral circulation and another that con-
sists in the development of 4 types of collateral circula-
tion. When 3 or less types of collateral circulation are de-
veloped, superior and inferior SR types are the most fre-
quent, and when four types exist PR and PE are the types
associated.
Diﬀerences were observed between subgroups IIa and
IIb in the development of collateral circulation. In the
group with lower spleen weight (IIa) most rats (88.88%)
had 3 or less types of collateral vessels, while in the group
with greater spleen weight (IIb) 71.43% developed four
types of collateral vessels, and this diﬀerence was statisti-
cally signiﬁcant (P = .005) (Table 2). There is, therefore, a
signiﬁcant correlation (P = .003) between splenic weight
and the number of newly formed collateral vessels.
The concentrations of proinﬂammatory cytokines
TNF-α and IL-1β in ileum do not increase in rats with
PHT(Figure2).Incontrast,IL-10levelsincrease(P<. 01)
in these animals. TNF-α and IL-1β levels increase in the
liver (P<. 05 and P<. 001, resp) (Figure 3).
Liver and intestinal eNOS activity is similar in control
and portal hypertensive-rats (Table 4). On the contrary,
iNOS activity increases in liver (P<. 001) and in jejunum
(P<. 05) in PHT rats (Table 5).
As shown in Figures 4 and 5,i nr a t sw i t hP H TN O
and CO of hepatic source increase (P = .005) while NO
decreases in IH-IVC (P = .005).
DISCUSSION
In rats with short-term prehepatic PHT, there is an
ileum release of IL-10 which is associated with hepatic
production of both proinﬂammatory mediators (TNF-
α,I L - 1 β, and NO) and an antiinﬂammatory mediator
(CO).
IL-10 is a pleiotropic and regulator cytokine pro-
ducedprincipally by bothT cellsandmacrophages,which
possessesbothantiinﬂammatoryandimmunosuppressive
properties [24]. In PHT, IL-10 of ileum origin can be
produced by T an B lymphocytes of the gut-associated-
lymphatic-tissue (GALT), monocytes/macrophages, and
mast cells since all these cells are well-known sources of
IL-10 [25]. The production of IL-10 is triggered by sev-
eral stress factors and its concentrations in the blood and
in tissue compartments often reﬂect the magnitude of the
inﬂammatory stress [24]. Experimental studies in rodents
and primates have revealed that the primary inducers of
IL-10 synthesis are in fact more proximal proinﬂamma-
tory cytokines, such as TNF-α and IL-1 [24]. Moreover,
glucocorticoids, endotoxin, and reactive oxygen interme-
diates, all raised in PHT, have been shown to induce IL-10
release [15, 24, 26, 27].
In portal hypertensive rats it has been demonstrated
that in the short term (1, 14, and 45 days postop-
eration) the serum concentrations of TNF-α,o n eo f
the factors to which the hyperdynamic syndrome is at-
tributed, increase [28, 29]. Bacteria colonizing the gut
represent a large reservoir of microbial products, such
as lipopolysacharides (LPS), endotoxins and other bacte-
rial wall fragments capable of inducing inﬂammatory cy-
tokines and lead to sustained NO production [30]. GALT
hasbeenshowntoproduceandreleaseTNFinresponseto
bacterialtranslocation,sothegutisa“cytokine-releasing”
organ in PHT [30].
It can be hypothesized that immediately post PHT
splanchnic hyperpressure could trigger an intestinal in-
ﬂammatory reaction that would be highly tissue damag-
ing and could require activation of NF-κB with ensuing
generation of chemokines and cytokines in a shorter de-
velopmental period than one month p.o. Then, intestinal2005:2 (2005) Inﬂammatory Mediators in Portal Hypertension 105
Table 1. Body weight increase (BWI), liver weight (LW), liver weight to body weight (BW), spleen weight (SW), and spleen weight
to body weight in the control group (Group I) and in rats with triple stenosing ligation of portal vein (TSLP) (Group II) which, in
turn, were divided into Groups IIa (SW/BW < 0.29) and IIb (SW/BW ≥ 0.30). The results are expressed as mean ± SD. ∗ denotes
that P<. 05 in relation to control group, ∗∗ denotes that P<. 01 in relation to control group, and ∗∗∗denotes that P<. 001 which
is a statistically signiﬁcant value in relation to the control group. •••denotes that P<. 001 which is a statistically signiﬁcant value of
Group IIb in relation to Group IIa.
Group BWI (g) LW (g) LW/100 g BW SW (g) SW/100 g BW
I (control) 140 ±30 13.4 ±1.13 .4 ±0.15 0.7 ±0.13 0.18 ±0.04
n = 11
II (TSLP) 62 ±38∗∗∗ 11 ±2.5∗∗∗ 3.5 ±0.81 .0 ±0.2∗∗∗ 0.3 ±0.06∗∗∗
n = 23
IIa (TSLP) 78 ±40∗∗∗ 10.1 ±1.5∗∗ 3.1 ±0.25 0.9 ±0.12∗ 0.3 ±0.02∗∗∗
n = 9
IIb (TSLP) 52 ±34∗∗∗ 11.1 ±2.9∗ 3.7 ±11 .1 ±0.13∗∗∗ 0.4 ±0.04∗∗∗,•••
n = 14
Table 2. Portal pressure (PP), mesenteric vasculopathy (MV), and portosystemic collateral circulation (CC) in control rats (Group
I) and in rats with triple stenosing ligation of portal vein (TSLP) (Group II) which, in turn, were divided into Group IIa (spleen
weight/body weight < 0.29) and Group IIb (spleen weight/body weight ≥ 0.30). The results are expressed as mean ± SD. ∗∗∗
denotes that P<. 001 which is a statistically signiﬁcant value relative to the control group. •• denotes that P = .005 which is a
statistically signiﬁcant value of Group IIb relative to Group IIa.
Group PP MV CC
mmHg Grade I Grade II n ≤ 3n = 4
I (control) 7 ±0.6— — — —
(n = 11)
II (TSLP) 13 ±3.5∗∗∗ 11 (48%) 12 (53%) 12 (53%) 11 (48%)
(n = 23)
IIa (TSLP) 13 ±4∗∗∗ 5 (55.5%) 4 (44.4%) 8 (89%) 1 (11%)
n = 9
IIb (TSLP) 13 ±3.4∗∗∗ 6 (43%) 8 (57%) 4•• (28.6%) 10•• (71.4%)
n = 14
Table 3. Correlations between portal pressure and body weight increase and liver and spleen weights in rats with triple stenosing
ligation of portal vein (TSLP) (Group II) which, in turn, were divided into Group IIa (spleen weight/body weight < 0.29) and Group
IIb (spleen weight/body weight ≥ 0.30).
Correlations
Correlation (r)
TSLP (IIa+IIb) TSLP (IIa) TSLP (IIb)
PP versus BWI 0.57 (P = .004) 0.71 (P = .03) 0.56 (P = .03)
PP versus LW/BW −0.46 (P = .02) — −0.75 (P = .002)
PP versus SW/BW — — −0.68 (P = .008)
release of IL-10, a cytokine that controls inﬂammatory
processes by suppressing the production of proinﬂamma-
tory cytokines that are transcriptionally regulated by NF-
κB, would occur. Moreover, IL-10 also inhibits the release
of free oxygen radicals and NO [31]. More speciﬁcally,
IL-10 is a pivotal cytokine in the control of intestinal in-
ﬂammation and plays a central regulatory role in the im-
mune responses of the intestine, limiting and ultimately
terminating inﬂammatory responses [32]. It seems that
its main function is to keep the inﬂammation under strict
control by adjusting the intensity of the immune and in-
ﬂammatory responses to the severity of the destruction
produced by a pathological condition or a pathogen and,
thus, minimizing damage to the host tissues caused by ei-
ther the pathogen or the immune system itself [33]. In
this study, the intestinal production of IL-10, possibly act-
ing in a paracrine/autocrine fashion, would eﬀectively in-
hibit intestinal release of TNF-α,I L - 1 β, and NO. The in-
hibitory eﬀects of IL-10 on IL-1 and TNF production are
crucial to its antiinﬂammatory activities, because these
cytokines often have synergistic activities on inﬂamma-
tory pathways and processes, and amplify these responses
by inducing secondary mediators such as chemokines,
prostaglandins, and PAF [34].106 Maria Angeles Aller et al 2005:2 (2005)
Table 4.Liverandintestinalendothelialnitricoxidesynthase(eNOS)activityincontrolrats(GroupI)andinratswithtriplestenosing
ligation of portal vein (TSLP) after 28 days of evolution. The results are represented as mean ±SD.
Group eNOS liver eNOS duodenum eNOS jejunum eNOS ileum
µmol/pg protein µmol/pg protein µmol/pg protein µmol/pg protein
I (control) 1.1 ±0.55 .7 ±0.95 5 ±14 ±2.8
(n = 8)
II (TSLP) 1.45 ±0.47 ±0.96 .5 ±15 ±3.2
(n = 8)
Table 5. Liver and intestinal inducible nitric oxide synthase (iNOS) activity in control rats (Group I) and in rats with triple stenosing
ligation of portal vein (TSLP) (Group II) after 28 days of evolution. The results are represented as mean ±SD. ∗ denotes that P<. 05
and ∗∗∗P<. 001 which is a statistically signiﬁcant value in relation to the control group.
Group iNOS liver iNOS duodenum iNOS jejunum iNOS ileum
µmol/pg protein µmol/pg protein µmol/pg protein µmol/pg protein
I (control) 1 ±0.46 .0 ±0.75 .7 ± 0.95 .7 ±2.3
(n = 8)
II (TSLP) 3.8 ±0.8∗∗∗ 6.7 ±1.47 .3 ±1.3∗ 6.5 ±1.5
(n = 8)
However, the increase in IL-10 intestinal production
could have another meaning because IL-10, as well as in-
hibiting inﬂammation,
(1) has an important role in fetal wounds leading to re-
duced matrix deposition and scar-free healing [35],
(2) is expressed at elevated levels in chronic venous
ulcers and may be related to the failure of these
wounds to progress to ﬁnal wound healing [36],
(3) hasamodulatoryeﬀectonhepaticﬁbrogenesis,and
onhepatocyteproliferationandlimitslivernecrosis
[37].
If induction of proinﬂammatory cytokines in liver is
not counterbalanced by antiinﬂammatory cytokines, es-
pecially IL-10, there are inﬂammatory reactions leading
to massive liver damage and ﬁbrosis with pathologic pro-
gression to cirrhosis [38, 39]. Therefore, the intestinal rise
in IL-10 in PHT would prevent two severe consequences
of the proinﬂammatory response in a tissular area as large
as the intestine: an early response that would combine
necrosis and edema and a later one leading to intestinal
ﬁbrosis.
It could be hypothesized that in short-term portal hy-
pertensive rats proinﬂammatory gut-derived mediators
enter the liver directly through the PV or by an indirect
route through intestinal lymphatics and/or systemic cir-
culation. These gut-derived mediators would be a stim-
ulus for hepatic synthesis of TNF-α and IL-1β.H y p o x i c
stress has also been involved in cytokine synthesis by
Kupﬀer cells [26] and in the liver Kupﬀer cells are major
sources of proinﬂammatory cytokines that are produced
in response to LPS [40]. Since PHT by PVL causes portal
blood deprivation to the liver, it could be considered that
this proinﬂammatory factor associated to LPS presence in
portal circulation [41] could stimulate the Kupﬀer cells to
produce proinﬂammatory compounds, including TNF-α
and IL-1β.
In previous studies we have demonstrated that pro-
gressive liver steatosis is produced in rats with prehep-
atic PHT [42]a n dT N F - α and TNF-regulated cytokines
are considered as eﬀector molecules in nonalcoholic fatty
liver disease (NAFLD) ranging from steatosis to cirrho-
sis [43]. It has been accepted that liver injury requires
at least two “hits”: one that increases exposure of the
hepatocytes to TNF-α and another that interferes with
the fat metabolism and renders the liver more vulnera-
ble to a second injury, such as bacteria or LPS of intesti-
nal origin, because the hepatocytes become sensitized to
TNF-mediated cell death [43, 44]. TNF-α and other cy-
tokines inhibit mitochondrial oxidative phosphorylation,
with a decrease in free fatty acids (FFA) oxidation and
oxidative stress [45]. TNF-α and TNF-related cytokines
can contribute to the liver steatosis which occurs in PHT
both by reducing the hepatic oxidation of fatty acids and
by increasing lipid synthesis because IL-1 and, in par-
ticular TNF-α, stimulate hepatic lipogenesis in the rat
and increase the plasma levels of FFA and triglycerides
[46].
The direct biological response of TNF-α,w h i c hi s
ubiquitously expressed in response to stress, also referred
to as an “alarm hormone” [47], is ampliﬁed by the sec-
ondary release of other cytokines and metabolic prod-
ucts like IL-1 [47]a n dN O[ 48]. Our results show an in-
creased hepatic activity of iNOS 1 month after PVL. iNOS
is synthesized de novo principally in macrophages, vas-
cular smooth muscle cells, hepatic stellate cells, and hep-
atocytes, only after induction by LPS and inﬂammatory
cytokines [49], both of which are increased in this exper-
imental model. In 1991, Vallance and Moncada proposed2005:2 (2005) Inﬂammatory Mediators in Portal Hypertension 107
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Figure 2. Concentrations of (a) TNF-α,( b )I L - 1 β,a n d( c )I L -
10 in the ileum of control rats (Group I) and of rats with triple
stenosing ligation of portal vein (TSLP) (Group IIb) after 28
days of evolution.
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Figure 3. Concentrations of (a) TNF-α,( b )I L - 1 β,a n d( c )I L - 1 0
in liver of control rats (Group I) and in rats with portal hyper-
tension (PHT) by triple stenosing ligation of portal vein (TSLP)
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Figure 4. Nitric oxide (NO) in portal vein (PV), suprahepatic
inferior vena cava (SH-IVC), and infrahepatic inferior vena cava
(IH-IVC)incontrolrats(GroupI)andinratswithtriplestenos-
ing ligation of portal vein (TSLP) (Group IIb) after 28 days of
evolution.
that the increased synthesis and release of the vascular
endothelium-derived vasodilator ND, induced by endo-
toxin directly or indirectly by cytokines, could account
for the peripheral cardiovascular abnormalities of cir-
rhosis [50]. However, the main enzymatic source of the
NO systemic and splanchnic overproduction which oc-
curs in PHT [51] is eNOS, the constitutive isoform of
NOS. eNOS protein expression increases, eNOS activity
enhances and endothelial NO release is produced in re-
sponse to ﬂow and shear stress in mesenteric and systemic
vessels of PHT animals [49]. Models of PHT developed
by PV stenosis are associated with a chronic increase in
splanchnic shear stress, related to high blood ﬂow, which
may contribute to NO overproduction by upregulation
of eNOS [52]. This could represent an adaptive mecha-
nism of the endothelium in response to chronic increases
in ﬂow-induced shear stress [51, 53].
However, activation of iNOS in vascular smooth wall
has also been described in prehepatic PHT [54, 55]l e a d -
ing us to deduce that possibly a small part of NO derived
from iNOS, upregulated in mesentery vasculature, may
also contribute to hyperdynamic circulation in PHT [56].
The contribution of each isoform of NOS to the patho-
genesis of the hyperdynamic syndrome probably depends
on the etiology or severity of cirrhosis in human studies
and in animal studies on the PHT model [57]p e r h a p so n
the time considered after PVL and especially on the tissue
inwhichtheenzymeismeasured.Thiscouldcausethein-
creased eNOS shown in splanchnic and systemic vascular
beds [50, 51, 52] while we found an increased iNOS ac-
tivity in liver. Thus, 1 month after PVL our results suggest
that liver proinﬂammatory cytokines (TNF-α and IL-1β)
and endotoxin of intestinal origin could increase the hep-
atic synthesis of NO by iNOS upregulation.
In this early phase of PHT we have also shown the
increased hepatic synthesis of CO, which besides its va-
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Figure 5. Carbon monoxide (CO) in portal vein (PV), supra-
hepatic inferior vena cava (SH-IVC), and infrahepatic inferior
vena cava (IH-IVC) in control rats (Group I) and in rats with
triple stenosing ligation of portal vein (TSLP) (Group IIb) after
28 days of evolution.
sodilator and antiapoptotic eﬀects [58], is also an antiin-
ﬂammatory molecule [59]. Both isoforms of heme oxy-
genase (HO), the enzyme involved in the generation of
CO, the inducible and the constitutive ones, can be up-
regulated in PHT rats. Several physical or chemical fac-
tors that may be increased during PHT, including shear
stress, hypoxia, ND, glucagon, as well as the proinﬂam-
matory agents endotoxin and cytokines can induce HO-
1, the inducible isoform of HO [58]. HO-1 expression is
upregulated in hepatocytes and splanchnic organs from
PVL rats after 7 days of the operation [59]. In relation
to HO-2, the constitutive isoform of HO, the only chem-
ical inducers identiﬁed are adrenal glucocorticoids [60].
We have previously demonstrated that there is an increase
in plasma levels of corticosterone in rats with short-term
PVL [13] and therefore, HO-2 could be activated by glu-
cocorticoids in this experimental model.
The increase in serum CO levels after 1 month in
portal hypertensive rats could be related to their actions.
Thus, CO acts as an endogenous regulator that is required
for maintaining hepatic microvascular blood ﬂow [61]. In
addition, CO acts as a potent antiinﬂammatory molecule
that selectively inhibits expression of the proinﬂamma-
tory cytokines TNF-α,I L - 1 β and macrophage inﬂamma-
tory protein-1β (MIP-1β)[ 62].
In this early stage of prehepatic PHT in the rat, the
hepatic hyperproduction of proinﬂammatory cytokines,
that is, TNF-α and IL-1β,a sw e l la so fN Oa n dC O ,
could favor the development of mesenteric vasculopathy
with splanchnic arteriolar vasodilation and systemic hy-
perdynamiccirculation.Thedilationandtortuosityofthe
mesenteric vein branches, which we have called mesen-
tericvasculopathyandthatalsohavebeendescribedinas-
sociation with amarked dilation in microcirculation [63],
are signs that can be attributed to intestinal inﬂammation
in this PHT experimental model.2005:2 (2005) Inﬂammatory Mediators in Portal Hypertension 109
In this early state of prehepatic PHT, a gut-liver in-
ﬂammatory loop could be proposed. Proinﬂammatory
gut-derived mediators produced initially in response to
sharp and sudden PHT would be a stimulus for hepatic
synthesisofTNF-αandIL-1β,withiNOSactivation.Liver
TNF-αandIL-β,NOandCO,inturn,couldleavetheliver
and enter the gut to complete the inﬂammatory loop via
bile and/or the systemic recirculation.
It has been shown that in rats with portocaval anasto-
mosis the spleen size reﬂects portal pressure, and preser-
vation of portal pressure attenuates the shunt seque-
lae and provides metabolic and nutritional beneﬁts [23].
However, in a group of rats with PHT, spleen weight is in-
versely correlated with portal pressure (Table 3). In these
animals portal pressure has an inverse correlation with
spleen/body weight and liver/body weight ratios. More-
over, portal pressure and spleen weight are related with a
greater development of collateral circulation (Table 2). All
the above mentioned ﬁndings suggest that this subgroup
of animals represents one type of PHT which is character-
ized by hepatosplenomegaly and a great development of
portosystemic collateral circulation.
PHT results from a pathological increase in either
portal venous inﬂow (“forward hypothesis”) or resistance
(“backward hypothesis”) and the maintenance of an ele-
vated portal pressure depends, in part, on enhanced por-
tal collateral resistance [2]. It could, therefore, be consid-
eredthatinthisgroupofanimalsthegreaterdevelopment
of collateral circulation could be involved in regulating
mesenteric ﬂow and, subsequently, in controlling portal
pressure.
Although PHT has been considered as a uniform ex-
perimental model, the results described previously could
suggest an evolutive heterogeneity in this model. If we
consider that in this subgroup of portal hypertensive
rats, TNF-α and IL-1β are involved in the production
of hepatomegaly and that this increased liver size is sec-
ondary to steatosis, then the hyperproduction of IL-10
by the gut would be a mechanism, not only to decrease
the inﬂammatory response, but also to attenuate one
of its pathologic consequences, steatosis. Finally, the co-
existence of greater spleen weight and greater develop-
ment of collateral circulation could help to formulate
a physiopathological deﬁnition of an evolutive type of
PHT.
In summary, a hepatointestinal relationship seems to
play an essential role in regulating both the portal pres-
sureand its complications. This is only logical becausethe
gut-liver axis is a portal system and its functions are dis-
tributed along this axis.
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